Satralizumab shows benefit for thyroid eye disease in phase 3 trials

Two identically designed phase 3 trials, SatraGO-1 and SatraGO-2, evaluated subcutaneous satralizumab, an anti-interleukin-6 receptor antibody, against placebo in participants with active or inactive thyroid eye disease. At week 24, the trials reported that satralizumab was associated with higher rates of proptosis response, Clinical Activity Score reduction, disease inactivation, and diplopia improvement compared with placebo, though not all comparisons reached statistical significance; the trials also reported that satralizumab was well tolerated with low rates of serious adverse events and no serious infections.

Most relevant for: Patients with active or inactive moderate to severe thyroid eye disease being considered for interleukin-6 pathway-targeted therapy.

Summary written by an AI model from the source text and dated by the source's publication date. Check the original before acting on it. How MedFollow selects and summarizes updates.

Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.